Correction to: A Needs Assessment for Infectious Diseases Consultation in Community Hospitals
(Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - June 28, 2023 Category: Infectious Diseases Source Type: research
Quantifying the Economic and Clinical Value of Reducing Antimicrobial Resistance in Gram-negative Pathogens Causing Hospital-Acquired Infections in Australia
ConclusionThese estimates demonstrate the consequences of failure to combat AMR in the Australian context. The benefits in mortality and health system costs justify consideration of innovative reimbursement schemes to encourage the development and commercialisation of new effective antimicrobials. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - June 21, 2023 Category: Infectious Diseases Source Type: research
Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Na ïve, Compensated Cirrhotic HCV Patients
ConclusionEarly real-world evidence indicates high effectiveness of the 8-week G/P regimen in TN/CC patients of HCV genotypes 1 –6 from a large US claims database. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - June 17, 2023 Category: Infectious Diseases Source Type: research
Pharmacokinetics, Efficacy, and Safety of a SARS-CoV-2 Antibody Treatment in Pediatric Participants: An Open-Label Addendum of a Placebo-Controlled, Randomized Phase 2/3 Trial
ConclusionWBD in pediatric participants achieved similar drug exposures compared to adult participants that received the authorized BAM + ETE dose. The pediatric efficacy and safety data were consistent with adults receiving mAbs for COVID-19.Trial Registration NumberNCT04427501. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - June 17, 2023 Category: Infectious Diseases Source Type: research
Real-World Effectiveness of 8-Week Glecaprevir/Pibrentasvir in Treatment-Na ïve, Compensated Cirrhotic HCV Patients
ConclusionEarly real-world evidence indicates high effectiveness of the 8-week G/P regimen in TN/CC patients of HCV genotypes 1 –6 from a large US claims database. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - June 17, 2023 Category: Infectious Diseases Source Type: research
Pharmacokinetics, Efficacy, and Safety of a SARS-CoV-2 Antibody Treatment in Pediatric Participants: An Open-Label Addendum of a Placebo-Controlled, Randomized Phase 2/3 Trial
ConclusionWBD in pediatric participants achieved similar drug exposures compared to adult participants that received the authorized BAM + ETE dose. The pediatric efficacy and safety data were consistent with adults receiving mAbs for COVID-19.Trial Registration NumberNCT04427501. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - June 17, 2023 Category: Infectious Diseases Source Type: research
Decreasing Antibiotic Resistance Trends Nationally in Gram-Negative Bacteria Across United States Veterans Affairs Medical Centers, 2011 –2020
ConclusionWe observed significant decreases in antibiotic resistance forP. aeruginosa and Enterobacterales over the past decade. According to the 2020 antibiogram, in vitro antimicrobial activity was observed for most treatment options. These results may be related to the robust infection control and antimicrobial stewardship programs instituted nationally among VAMCs. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - June 16, 2023 Category: Infectious Diseases Source Type: research
Assessing Public Health Impact of Four Pediatric Pneumococcal Conjugate Vaccination Strategies in the Netherlands
ConclusionsFor the Dutch pediatric NIP, switching to PCV13 in 2023 would be an effective strategy compared with continued use of PCV10 for averting pneumococcal disease cases. Switching to PCV20 in 2024 was estimated to avert the most pneumococcal disease cases and provide the highest protection. However, in the face of budget constraints and the undervaluation of prevention strategies, it remains challenging to implement higher valent vaccines. Further research is needed to understand the cost-effectiveness and feasibility of a sequential approach. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - June 15, 2023 Category: Infectious Diseases Source Type: research
Decline in Antimicrobial Consumption and Stagnation in Reducing Disease Burden due to Antimicrobial Resistance in Japan
ConclusionsOur results reveal that changes in AMC are not associated with DALYs caused by AMR-BSIs. AMR countermeasures besides efforts to reduce inappropriate AMC might be necessary to mitigate the disease burden due to AMR. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - June 15, 2023 Category: Infectious Diseases Source Type: research
Assessing Public Health Impact of Four Pediatric Pneumococcal Conjugate Vaccination Strategies in the Netherlands
ConclusionsFor the Dutch pediatric NIP, switching to PCV13 in 2023 would be an effective strategy compared with continued use of PCV10 for averting pneumococcal disease cases. Switching to PCV20 in 2024 was estimated to avert the most pneumococcal disease cases and provide the highest protection. However, in the face of budget constraints and the undervaluation of prevention strategies, it remains challenging to implement higher valent vaccines. Further research is needed to understand the cost-effectiveness and feasibility of a sequential approach. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - June 15, 2023 Category: Infectious Diseases Source Type: research
Decline in Antimicrobial Consumption and Stagnation in Reducing Disease Burden due to Antimicrobial Resistance in Japan
ConclusionsOur results reveal that changes in AMC are not associated with DALYs caused by AMR-BSIs. AMR countermeasures besides efforts to reduce inappropriate AMC might be necessary to mitigate the disease burden due to AMR. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - June 15, 2023 Category: Infectious Diseases Source Type: research
Mendelian Randomization Analysis Reveals Causal Associations of Polyunsaturated Fatty Acids with Sepsis and Mortality Risk
ConclusionOur study supported the casual effect between PUFAs and susceptibility to sepsis and sepsis-related death. Our findings underline the importance of specific PUFAs levels, particularly for individuals with a genetic susceptibility to sepsis. Further research is needed to confirm these findings and investigate the underlying mechanisms. (Source: Infectious Diseases and Therapy)
Source: Infectious Diseases and Therapy - June 14, 2023 Category: Infectious Diseases Source Type: research
